European Medicines Verification System establishes link with German repository system

23 July 2015
eu-european-union-flag

A link has been established between the European Medicines Verification System and the German repository system, marking the first successful implementation of a Hub connection with a member state.

This is part of the drive to secure the legitimate pharmaceutical supply chain against the risk of falsified medicines. The link between the European hub and the German repository system, managed by the stakeholder organization securPharm, was established on July 1. This means that pharmaceutical manufacturers will now be able to upload their serialized data onto the system.

About 700 million packages of prescription drugs per year will have to be printed with a so-called Data Matrix Code that includes an individual serial number, thereby rendering each package unique. Almost all production lines must be converted to include the new security features.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical